X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
Summary
X4 Pharmaceuticals has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization for mavorixafor in the EU for WHIM syndrome. This is a critical regulatory milestone, positioning mavorixafor as a potential first and only therapy for this ultra-rare immune disorder in Europe, following its prior FDA approval in the U.S. The positive opinion significantly de-risks the European market entry and expands the drug's commercial reach. X4 has a licensing agreement with Norgine, which includes up to €226 million in potential regulatory and commercial milestones, alongside escalating double-digit royalties, representing a material financial upside for the company. Investors will now await the European Commission's final approval decision, anticipated in the second quarter of 2026, and subsequent commercialization efforts.
At the time of this announcement, XFOR was trading at $3.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $284.2M. The 52-week trading range was $1.35 to $13.53. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.